O
RVNC icon

OppenheimerFunds’s Revance Therapeutics, Inc. RVNC Stock Holding History

OppenheimerFunds’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-252,370
Closed -$6.93M – 1840
2018
Q2 		$6.93M Buy
252,370
+24,284
+11% +$730K 0.01% 753
2018
Q1 		$7.03M Buy
+228,086
New +$7.34M 0.01% 737

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds's RVNC Position: Q3 2018 in Review

OppenheimerFunds sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2018, closing a stake of 252,370 shares — an estimated $6.93M sold.

OppenheimerFunds first reported a position in RVNC in Q1 2018 and held it in 2 quarters. The position peaked at $7.03M in Q1 2018. 110 funds tracked by Wall St. Rank hold RVNC as of Q3 2018.

  • OppenheimerFunds reported no remaining Revance Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • OppenheimerFunds sold 252,370 Revance Therapeutics, Inc. shares in Q3 2018, an estimated $6.93M.
  • OppenheimerFunds first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
  • OppenheimerFunds's Revance Therapeutics, Inc. position peaked at $7.03M in Q1 2018.
  • 110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2018.

Based on OppenheimerFunds's 13F filing for Q3 2018, filed 13 Nov 2018.